-0.0026 (-0.2179%)
+0.0020 (+0.1475%)
Has Amtech Systems (ASYS) Outpaced Other Computer and Technology Stocks This Year?
Investors interested in Computer and Technology stocks should always be looking to find the best-performing companies in the group. Amtech Systems (ASYS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Computer and Technology sector should help us answer this question.
Amtech Systems is a member of our Computer and Technology group, which includes 638 different companies and currently sits at #10 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ASYS is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ASYS's full-year earnings has moved 112.61% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ASYS has returned 21.19% so far this year. Meanwhile, stocks in the Computer and Technology group have gained about 17.59% on average. This shows that Amtech Systems is outperforming its peers so far this year.
Looking more specifically, ASYS belongs to the Semiconductor - General industry, a group that includes 8 individual stocks and currently sits at #109 in the Zacks Industry Rank. On average, this group has gained an average of 11.53% so far this year, meaning that ASYS is performing better in terms of year-to-date returns.
ASYS will likely be looking to continue its solid performance, so investors interested in Computer and Technology stocks should continue to pay close attention to the company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amtech Systems, Inc. (ASYS) : Free Stock Analysis Report
Zacks Investment Research
We look at a Ethereum as a crypto-cloud stock and the next possible step of cloud computing: Fundstrat Strategist
Vice President Kamala Harris now lives in this house
Trump impeachment trial could hinder Biden's agenda: AGF Investments chief US policy strategist
What investors can expect during Biden's first 100 days as President
The sell-off also led to major corrections for other cryptocurrencies including ether, stellar, xrp and chainlink.
The U.S.-listed shares of BlackBerry Ltd. surged 4.4% toward a near three-year high in afternoon trading Wednesday, to extend the record rally over the past several days. The Canada-based cyber-security software company's stock has been on a tear over the past week, after The Global and Mail reported that the company, which made BlackBerry cellphones in a past life, had sold 90 patents to China-based technology giant Huawei, and after the company reportedly settled a patent infringement lawsuit against Facebook Inc. . The stock, on track to close at the highest price since March 2018, has soared 73.3% amid a four-day win streak. That's would be the best four-day performance for the stock since it started trading in February 1999, according to a MarketWatch analysis of FactSet data; the current record four-day rally is 65.7%, set over the four sessions ended June 2, 2000. The stock has now rocketed 153.7% over the past three months, while ETFMG Prime Cyber Security ETF has climbed 26.0% and the S&P 500 has gained 12.0%.
Stock Market Today With Jim Cramer: Buy Ford
Jim Cramer discusses the latest stock market news including Ford stock, Procter & Gamble's earnings and the executive orders by president Joe Biden.
Is Caladrius Stock a Buy Right Now? This Is What You Need to Know
On Wednesday, shares of clinical-stage biopharmaceutical company Caladrius Biosciences (CLBS) took off by a whopping 110%. However, the surge did not come off the back of a treatment's regulatory approval or the release of positive clinical trial results. Seemingly more prosaic, investors appeared to cheer the news that the company has treated its first patient in the Phase 2b FREEDOM Trial of CLBS16, the small biotech's candidate for the treatment of coronary microvascular dysfunction (CMD). The double-blind, placebo-controlled study kicked off at the Christ Hospital Health Network in Cincinnati, Ohio and, overall, by the end of the year, 105 patients are expected to enroll across several sites in the U.S. The trial's objective is to further assess the effectiveness and safety of the intracoronary delivery of autologous CD34+ cells in patients with CMD and without obstructive coronary artery disease. The company anticipates to have top-line data available by 3Q22. Covering the stock for H.C. Wainwright, analyst Joseph Pantginis commented, "With the FREEDOM trial, CLBS16 is poised to replicate its performance in a larger population of CMD patients in a blinded fashion, therefore solidifying the basis for key discussions with the FDA around its path to approval." The excitement around the trial's initiation might be down to the fact the treatment has a good track record already. The analyst reminds investors, that in spring 2020, the company reported that CLBS16 demonstrated "compelling Phase 2a data of safety and efficacy." The data showed that in 19 out of 20 CMD patients, a single administration of CLBS16 markedly improved the coronary flow reserve (CFR) and angina symptoms. Pantginis highlights how CLBS16 could prove to be unique, when compared to other CMD treatments. "We note that based on CLBS16's MoA (mechanism of action) the benefits experienced by the patients originate from revascularization, therefore are expected to be durable and to contribute to the restoration of the cardiac tissue functionality in the long term," the 5-star analyst said. "This element is a key differentiating factor of CLBS16 from current treatments, and together with the significant amelioration of symptoms, should resonate well with physicians and regulators." If you think you might have missed the boat following Wednesday's massive share haul, Pantginis thinks otherwise. Even after the surge, Pantginis' price target stands at $14, implying additional upside of ~306% could be at play over the following months. Unsurprisingly, the analyst sticks to a Buy rating. (To watch Pantginis' track record, click here) Pantginis is currently the only analyst to have posted a review over the past 3 months. It will be interesting to see if other Street analysts take notice. (See CLBS stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Top Dividend Stocks for February 2021
These are the top dividend stocks in the Russell 1000 with the highest forward dividend yield for February.
FuelCell Energy's Earnings Outlook
FuelCell Energy (NASDAQ:FCEL) will be releasing its next round of earnings this Thursday, January 21. For all of the relevant information, here is your guide for Thursday's Q4 earnings announcement.What Are Earnings, Net Income, And Earnings Per Share? Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.Earnings And Revenue Based on FuelCell Energy management projections, analysts predict EPS of $0.04 on revenue of $17.05 million. In the same quarter last year, FuelCell Energy reported a loss per share of $0.12 on revenue of $11.04 million.What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.View more earnings on FCELThe Wall Street estimate would represent a 66.67% increase in the company's earnings. Revenue would be up 54.42% from the year-ago period. In comparison to analyst estimates in the past, here is how the company's reported EPS stacks up:Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020 EPS Estimate -0.06 -0.07 -0.08 -0.11 EPS Actual -0.07 -0.07 -0.20 -0.12 Revenue Estimate 16.05 M 15.55 M 14.91 M 11.51 M Revenue Actual 18.73 M 18.88 M 16.26 M 11.04 M Stock Performance Shares of FuelCell Energy were trading at $18.125 as of January 19. Over the last 52-week period, shares are up 884.1%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.Do not be surprised to see the stock move on comments made during its conference call. FuelCell Energy is scheduled to hold the call at 10:00:00 ET and can be accessed here.See more from Benzinga * Click here for options trades from Benzinga * Understanding FuelCell Energy's Unusual Options Activity * 12 Industrials Stocks Moving In Friday's Intraday Session(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Cramer Gives His Opinion On Canopy Growth, Quanta Services And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would rather buy Penn National Gaming, Inc (NASDAQ: PENN) and Draftkings Inc (NASDAQ: DKNG) instead of Fubotv Inc (NYSE: FUBO).Cramer would be careful with Nano Dimension Ltd - ADR (NASDAQ: NNDM) because of a big move higher. These moves tend to have another leg up, but he doesn't want to be too aggressive.Canopy Growth Corp (NASDAQ: CGC) is a way to play the marijuana space, thinks Cramer.CIIG Merger Corp (NASDAQ: CIIC) is a good spec, said Cramer.Everything Michael Klein has been involved with, Cramer has liked it. But he thinks Churchill Capital Corp IV (NYSE: CCIV) is speculative.Quanta Services Inc (NYSE: PWR) has more room on the upside, thinks Cramer.See more from Benzinga * Click here for options trades from Benzinga * Tony Zhang Sees More Upside to GM, Lays Out Bullish Options Trade * Carter Worth And Mike Khouw's XLU Trade(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.